Selumetinib for Neurofibromatosis
This trial will test whether selumetinib can shrink plexiform neurofibromas in people with NF1.
- Neurofibromatosis Type 1
- Plexiform Neurofibroma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2012 Phase 2 trial • 37 Patients • NCT01085214
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are the findings of this study corroborated by prior research on Selumetinib?
"Selumetinib was first studied in 2007 and, since then, 18297 clinical trials have completed. Right now, 35 trials are ongoing with a large number of them based in Saint Louis, Missouri."
Has Selumetinib been cleared by the FDA for patient use?
"Selumetinib's safety has been well documented in past Phase 3 trials, thus it received a score of 3."
Are there any patients currently needed for this clinical trial?
"Yes, this information is available on the website clinicaltrials.gov. The trial was created on 2021-11-19 and updated on 2022-10-04."
What is the objective of this research?
"The primary outcome that will be measured over the course of approximately 3 years is the Confirmed Objective Response Rate (ORR) for Arm A versus Arm B. Additionally, this trial will evaluate secondary outcomes including Change in chronic target PN pain intensity from baseline for Arm A versus Arm B as assessed using a PRO questionnaire, Target PN volume for Arm A vs Arm B, and Time to progression (TTP) for Arm A."
Have there been other studies like this one before?
"There are 35 concurrent trials worldwide for Selumetinib. The first one was sponsored by AstraZeneca in 2007 and completed Phase 1 drug approval with 58 participants. Since then, there have been 18297 more trials."
What is the total sample size for this research project?
"Yes, the information on clinicaltrials.gov suggests that this study is actively recruiting candidates. The trial was originally posted on 2021-11-19 and was most recently edited on 2022-10-04. The study is looking for 146 patients across 7 locations."